ECTRIMS 2021 | Updates on RADIUS-R & RADIUS-P: elezanumab for patients with relapsing and progressive forms of MS

Elezanumab is a monoclonal antibody directed against repulsive guidance molecule A (RGMa), an inhibitor of neuronal regeneration critical in the formation of correct neural connections. RGMa is dysregulated in a range of diseases including multiple sclerosis (MS). Pre-clinical models suggested elezanumab might promote axonal growth and sprouting in the setting of nerve injury. Bruce Cree, MD, PhD, MAS, University of California San Francisco, San Francisco, CA, discusses the design and results of RADIUS-R (NCT03737851) and RADIUS-P (NCT03737812), two randomized double-blind, placebo-controlled studies evaluating the safety and efficacy of elezanumab in combination with standard of care (SOC) therapy in patients with relapsing (RADIUS-R) and progressive (RADIUS-P) forms of MS over one year. The primary endpoint was the overall response score (ORS), derived from three performance assessments evaluating changes in disability. Results showed no difference between elezanumab and placebo in both studies, suggesting that this drug does not help to restore neurological deficits in MS. Nevertheless, elezanumab is currently being developed for other indications including stroke and spinal cord injury. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.